RNA Editing in TCGA

[PMID: 26439496] [Cancer Cell]

The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers

Many clinically relevant RNA editing events are in noncoding regions. Nonsynonymous RNA editing may affect drug sensitivity. “A-to-I editing is a major source of mRNA variability in breast and other cancers. RNA editing is globally controlled by tumor interferon and ADAR copy number.” [PMID:26440892] “Extensive editing in cancer introduces RNA diversity or RNA mutations. RNA modification events in tumors are as abundant as genomic DNA mutations.” [PMID: 26440895] Will Yoav Gilad and Jonathan Pritchard comment on this?


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s